On May 13, 2025, CNS Pharmaceuticals, Inc. announced a public offering of 325,000 shares and warrants, expecting to raise approximately $5 million, with the closing of the sale occurring on May 14, 2025. They plan to use the proceeds for working capital and general corporate purposes.